DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
May 13, 2024, 16:05 ET – FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis – Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif., May 13, 2024 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, […]
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update Read More »